logo
Dairy at bedtime could be affecting your sleep

Dairy at bedtime could be affecting your sleep

Yahoo08-07-2025
People who have trouble sleeping are being urged to cut one dairy product from their bedtime routines.
New studies have shown that consuming cheese could be causing disturbed sleep and frequent nightmares.
Experts say they have found a strong link between getting nighttime terrors and having a form of lactose intolerance.
Researchers questioned more than 1,000 students at Canada's MacEwan University about their sleep, eating habits, and any perceived tie between the two.
Almost a third of those asked admitted to having regular nightmares with the majority of these respondents women.
Females were also more likely to remember their dreams and nearly twice as likely as men to know that they had a food allergy or intolerance.
40 per cent of the students said they thought that eating late at night or eating specific foods had affected their sleep, while a quarter believed that consuming certain foods could make their sleep worse.
The study found that people with less healthy diets were more likely to have bad dreams and less likely to remember their dreams.
From comparing the data collated, the experts compared reports of food intolerances to those of bad dreams and poor sleep, and found that 'lactose intolerance was associated with gastrointestinal symptoms, nightmares, and low sleep quality'.
Lead researcher Dr Tore Nielsen, who helped collate the findings from the University of Montreal, said: 'Nightmare severity is robustly associated with lactose intolerance and other food allergies.
'These new findings imply that changing eating habits for people with some food sensitivities could alleviate nightmares. They could also explain why people so often blame dairy for bad dreams.
'Nightmares are worse for lactose-intolerant people who suffer severe gastrointestinal symptoms and whose sleep is disrupted. This makes sense, because we know that other bodily sensations can affect dreaming.'
Some 'grate' advice has been issued by top scientists who think they may have found the remedy to enjoying a peaceful night of slumber.
Stomach pain from consuming dairy before laying down for the night plus gas during the night can affect sleep, researchers say, adding that the way to a getting a fully rested night could be as simple as cutting out cheese.
Not consuming the dairy product could help improve sleep quality, which may already be disrupted thanks to a number of outside factors such as noise and light pollution or other health issues.
Now, the authors are hoping to continue their studies to get a more in depth look at the impact certain foods have on our sleep quality.
Nielsen added: 'We need to study more people of different ages, from different walks of life, and with different dietary habits to determine if our results are truly generalizable to the larger population.'
The full findings have been published in journal Frontiers in Psychology.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025

Yahoo

time2 hours ago

  • Yahoo

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025

NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen's overall clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease in the U.S. and Canada. Additionally, a nonclinical study revealed sabirnetug achieved the highest selectivity for AβOs over Aβ monomers relative to recombinant lecanemab and aducanumab. The results are being presented at the Alzheimer's Association International Conference (AAIC), taking place July 27-31, 2025, in Toronto and online. 'These advances represent important progress in addressing the critical need for effective treatments targeting toxic amyloid β oligomers (AβOs) in early symptomatic Alzheimer's disease, while simultaneously demonstrating patient-centric and cost-effective trial execution strategies,' said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. 'By combining cutting-edge therapeutic development with smart clinical trial strategies, we're working to create a more efficient path forward in bringing potential new options to patients with Alzheimer's disease. " ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing Phase 2 study of sabirnetug in early Alzheimer's disease Acumen reported operational innovations in its ALTITUDE-AD Phase 2 clinical trial where researchers implemented an innovative two-step screening process using plasma pTau217 biomarker assay testing that yielded significant clinical trial screening and cost efficiencies. The approach reduced total screening costs by approximately 40% across U.S. and Canadian sites. Furthermore, the screening process was efficient, with 48% of participants meeting the pTau217 threshold required for confirmatory testing. Among those who passed this initial screening, 81% of participants successfully met amyloid positivity eligibility requirements. The strategy performed as intended, helping to achieve strong enrollment rates and reducing unnecessary amyloid PET scans and lumbar puncture procedures for potential participants. Sabirnetug shows superior selectivity for Aβ oligomers over monomer, a differentiated mechanism of action. Soluble, synaptotoxic AβOs are an early and persistent driver of AD-related pathophysiology and represent a key target for the development of next-generation therapies for Alzheimer's disease. Targeting soluble AβOs may slow down neurodegeneration, reduce tau hyperphosphorylation, and prevent synapse loss for patients with early AD. Acumen demonstrated sabirnetug's selectivity for binding to toxic AβOs through comprehensive surface plasmon resonance testing. The study revealed sabirnetug achieved the highest binding affinities to AβO preparations among the monoclonal antibodies tested. Sabirnetug also showed minimal interaction with monomeric Aβ, which is significant given that monomeric forms are approximately 7,000-fold more abundant than oligomers in the cerebrospinal fluid of patients with MCI and mild dementia due to AD. Overall, sabirnetug demonstrated 8,750-fold selectivity for Aβ1-42 stabilized oligomers over Aβ1-40 monomers. The results support sabirnetug's mechanism of action and selectivity for AβOs. About Sabirnetug (ACU193) Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer's disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD. About ALTITUDE-AD (Phase 2) Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on NCT identifier NCT06335173. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as 'potential,' 'will' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential and potential clinical efficacy of Acumen's product candidate, sabirnetug (ACU193) and the efficiencies and costs associated with the pTau217 screening assay. These statements are based upon the current beliefs and expectations of Acumen's management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ('SEC'), including in Acumen's most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. Investors:Alex Braunabraun@ Media:Jon YuICR HealthcareAcumenPR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Concierge Medicine Market Size Worth USD 39.02 Billion by 2034 Amid Demand for Personalized Healthcare
Concierge Medicine Market Size Worth USD 39.02 Billion by 2034 Amid Demand for Personalized Healthcare

Yahoo

time2 hours ago

  • Yahoo

Concierge Medicine Market Size Worth USD 39.02 Billion by 2034 Amid Demand for Personalized Healthcare

The global concierge medicine market size is expected to be worth USD 39.02 billion by 2034, up from USD 21.77 billion in 2025 and is projected to register an impressive CAGR of 6.7% during the forecast period from 2025 to 2034. This growth is primarily driven by the rising demand for personalized and preventive healthcare services, as patients increasingly seek direct access to physicians, longer consultation times, and improved care continuity. Ottawa, July 28, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the concierge medicine market size has been accounted for USD 21.77 billion in 2025 and is predicted to rise from USD 23.23 billion in 2026 to approximately USD 39.02 billion by 2034. During 2025 to 2034, the market is expected to grow at a solid CAGR of 6.70%. The increased need for concierge medicine is driven by the emphasis on personalized and preventive care and improved patient satisfaction. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ Quick Insights: Concierge Medicine Market Key Takeaways In terms of revenue, the global concierge medicine market was valued at USD 20.40 billion in 2024. It is anticipated to reach over USD 39.02 billion by 2034. The market is poised to grow at a notable compound annual growth rate (CAGR) of 6.70% from 2025 to 2034. North America accounted for the largest market share of 43% in 2024. Asia Pacific is expected to grow at the fastest CAGR between 2025 and 2034. By application, the primary care contributed the highest market share of 27.3% in 2024. By application, the pediatrics segment is expected to grow at a strong CAGR from 2025 to 2034. By ownership, the group segment held the major market share of 64% in 2024. By ownership, the independent segment is expected to grow at the fastest CAGR during the forecast period. Concierge Medicine Market Overview and Industry Potential What is Concierge Medicine? Concierge medicine refers to the association between patients and physicians through which special care is provided to patients who reserve high-end premium packages in advance. It involves payments in the form of monthly or annual fixed fees for same-day appointments or 24/7 physician availability. This package encompasses pediatricians, urgent care clinics, house calls of the doctor, medical specialists, or primary care physicians. The healthcare professionals involved in these packages generally set their special appointments to visit and care only for their concierge service patients. Also Read @ How Concierge Medicine Complements the Precision Medicine Revolution in the U.S. Concierge medicine is redefining the patient-provider relationship by enabling faster, more personalized care,' said Rohan Patil, Principal Consultant at Precedence Research. 'As healthcare shifts toward individualized service models, this market is poised for transformative growth. Concierge Medicine Market Major Trends: What are the Major Trends in Concierge Medicine and Healthcare Membership? Integration of Telehealth: There is an integration of telehealth into concierge practices which is coupled with technological advancements and acceptance of virtual visits. It has resulted in increased utilization of resources and adherence to quality measures like accreditation. Telehealth assists in treating injuries, illness, and promotes longevity. Quality Care: For this purpose, several healthcare professionals such as nurse practitioners, membership models, concierge physician specialties, etc. are involved in concierge medicine practices. They impact access, the levels of quality of care, and cost. These practices ensure a balanced quality of care for patients. Discover the Complete Findings@ Concierge Medicine Market Growth Factors Why Should Patients Choose Concierge Services? No more Hurried Visits: People do not feel that their medical visits are going to be rushed due to the high workload of healthcare workers. Physicians stick to a strict appointment timeline to see every patient who needs medical care. Direct Access to Healthcare Provider: Patients undergoing medical care through concierge service packages experience good availability and accessibility of medical providers. The patients are always a priority of their healthcare professionals. What is the Role of the Cutting-edge Artificial Intelligence in the Concierge Medicine Market? Artificial Intelligence powered tools assist in image recognition, where they can analyze medical images with high precision. They can also identify abnormalities in the human body through medical images that cannot be seen through the human eye. These approaches are very useful in the dermatology and radiology fields. AI is not only enhancing image diagnostics but also powering personalized treatment planning, remote patient monitoring, and intelligent scheduling. Concierge platforms are leveraging AI chatbots for 24/7 communication, predictive analytics for early disease detection, and tailored wellness plans based on biometric data. MORE FOR YOU: ➢ AI in Healthcare Market Size, AI-Powered Diagnostics & Enhancing Accuracy ➢ How AI Is Reshaping Medical Imaging: A $14.46 Billion Market Opportunity by 2034 ➢ Medical Imaging on the Rise: Market Growth, Key Segments & Regional Outlook Opportunities in the Concierge Medicine Market In December 2024, Sollis Health announced the investment of $33 million in series B funding to boost product innovation, member experience, and expansion across the nation. (Source: In November 2024, Bajaj Finserv Health announced the investment of INR 1,000 Crore in technology and services to launch 'Health Saathi' concierge. (Source: Concierge Medicine Market Challenges and Limitations: What are the Key Problems associated with Concierge Medicine? Out-of-Pocket Costs: Personalized healthcare is related to its own price tag and patients feel a prohibitive membership fee. These out-of-pocket services may not be included under the prescriptions, concierge umbrella-like specialist visits, and hospital stays. Challenging Insurance Billing: Patients can face issues regarding transparency in healthcare services and insurance billing. This process involves endless phone calls, policies, and vague responses that can leave patients more baffled than informed. Out-of-pocket membership fees typically range between USD 1,500 to USD 5,000 annually in the U.S., depending on the level of service. This pricing model can limit access for middle-income populations and may not be covered by traditional insurance models. Also Read@ Why Hospitals Are Outsourcing Billing: Insights Into the USD 54 B Market Boom Scope of Concierge Medicine Market Report Attributes Statistics Market Size in 2024 USD 20.40 Billion Market Size in 2025 USD 21.77 Billion Market Size by 2034 USD 39.02 Billion Growth Rate (2025–2034) CAGR of 6.70% U.S. Market Size in 2025 USD 6.55 Billion U.S. Market Size in 2034 USD 1.97 Billion U.S. Market Growth Rate (2025–2034) CAGR of 6.88% Base Year 2024 Forecast Period 2025 to 2034 Dominant Market North America – due to higher adoption of retainer-based healthcare models Fastest Growing Region Asia Pacific – driven by rising demand for premium healthcare services Benefits for Buyers • Understand regional trends• Compare revenue share• Identify growth pockets and investment zones Segments Covered Application, Ownership, and Regions Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Top Companies Covered PartnerMD, Crossover Health, MDVIP, CONCIERGE CONSULTANTS & CARDIOLOGY, Signature MD, Peninsula Doctor, Winstead PC, Castle Connolly Private Health Partners, Specialdocs Consultants, LLC., Priority Physicians, Inc. Real‑World Case Studies: How Concierge Medicine Is Reshaping Healthcare 1) Human Longevity Clinic — Silicon Valley (2025) Case Summary:In early 2025, the Human Longevity Clinic in South San Francisco gained attention for offering ultra-premium, AI-integrated longevity plans priced between USD 8,000 and 19,000 per year. Patients undergo advanced diagnostics, including full-body MRIs, genome sequencing, cardiac scans, and blood panels, generating over 150GB of health data per client. Outcome Highlights: Detected early-stage aneurysms and tumors in asymptomatic patients. Personalized plans improved long-term prognosis through lifestyle interventions. AI tools assisted with anomaly detection, enhancing care quality beyond traditional diagnostics. Why It Matters:This example illustrates the growing appeal of preventive concierge models, blending precision diagnostics and tech-driven personalization. It aligns perfectly with your report's insights on AI integration, growing demand for preventive care, and willingness to pay for high-touch services. 2) Dr. Khalid Saeed's House Call Concierge Model — Tampa Bay, Florida (2023–2024) Case Summary:Dr. Khalid Saeed launched a concierge house-call practice offering personalized in-home and virtual care with monthly fees between USD 150–800, depending on patient complexity. His business model is insurance-free, catering to ~250 patients with 24/7 access. Outcome Highlights: Patients report dramatically reduced stress and stronger physician relationships. The practice operates profitably with minimal administrative burden. A blend of telehealth and in-person visits enables efficient chronic care management. Why It Matters:This model reflects the group and independent ownership trends cited in your report, showing how small-scale practices can thrive by offering personal, direct access to healthcare. It also supports your forecast for independent practices growing at the fastest CAGR during 2025–2034 Set up a meeting at your convenience to get more insights instantly! Concierge Medicine Market Regional Analysis: How North America Dominated the Concierge Medicine Market in 2024? North America dominated the concierge medicine market in 2024 owing to the increased demand for personalized care and chronic disease prevalence. This region is making efforts to accomplish its ambitious vision across infrastructure, health, science, tourism, technology, entertainment, and renewable energy. The U.S. makes partnerships with tech companies and investors to become a leader in next-generation technologies and digital infrastructure. Also Read@ Global Medical Tourism: How a USD 43.5 B Industry in 2025 Is Transforming Healthcare Trave How Big is the U.S. Concierge Medicine Industry? According to Precedence Research, the U.S. concierge medicine market size was valued at USD 6.14 billion in 2024 and is projected to reach USD 11.97 billion by 2034, growing at a CAGR of 6.88% from 2025 to 2034. Consumers are driving growth in this market by seeking personalized care, including direct physician access, longer consultations, and same- or next-day appointments, enabled by membership-based, low-patient-load models. U.S. Concierge Medicine Market – Key Takeaways By Application: The "Others" segment accounted for the largest market share in 2024, leading the U.S. concierge medicine landscape. Primary Care Segment: Expected to remain the second-largest application segment throughout the forecast period, demonstrating consistent demand and adoption. By Ownership: The group ownership model dominated the market in 2024, capturing the highest share among ownership types. Note: This Report is Readily Available for Immediate Delivery| Download the Sample Pages of this Report@ U.S. Concierge Medicine Market Top Companies Priority Physicians, Inc Castle Connolly Private Health Partners Partner MD Concierge Consultants and Cardiology U.S. Concierge Medicine Market Key Drivers: Physician Burnout & Shift in Practice Models: Many U.S. doctors are transitioning away from high-volume, insurance-based models to concierge practices to reduce administrative burdens and improve patient relationships. Consumer Demand for Better Access: Patients are willing to pay out-of-pocket fees (typically $1,500–$3,000/year) for longer appointments, direct communication, and same-day scheduling. Chronic Disease Prevalence: With rising cases of diabetes, obesity, and heart disease, concierge medicine allows for continuous care and lifestyle management that traditional practices often lack time for. Employer-Sponsored Concierge Care: Corporations are increasingly offering concierge medical services as a benefit to executives and high-performing employees, recognizing its value in reducing absenteeism and improving health outcomes. Japan Concierge Medicine Market Key Drivers: Aging Population & Chronic Disease Burden: With over 28% of Japan's population aged 65 and older, there is increasing demand for continuous care, home visits, and customized treatment plans, which concierge models are well-equipped to provide. Rising Interest in Preventive Health & Wellness: Japan's healthcare culture emphasizes longevity and wellness, aligning well with concierge medicine's focus on preventive screenings, lifestyle planning, and holistic care. High Expectations for Quality & Privacy: Wealthier patients and business executives in Japan are willing to pay premium fees for private, convenient, and responsive medical services, especially in metro areas like Tokyo, Osaka, and Yokohama. For instance, Tokyo-based startup 'PrimeDoc' launched a membership plan in 2024 targeting C-level executives and foreign residents, offering multilingual concierge services and AI-powered diagnostics. Corporate Adoption: Some high-end concierge services are being introduced by private hospitals and corporate health programs to cater to senior executives and foreign residents. For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@ How Asia Pacific is Moving towards Sustainable Development in 2025? Asia Pacific is expected to grow at the fastest CAGR in the concierge medicine market during the forecast period due to rising disposable income and growing healthcare awareness. The Economic and Social Commission for Asia and the Pacific and the regional platform make efforts to empower, inform, and support Asian Pacific countries to achieve sustainable development goals. These countries include less developed countries, small island developing states, and landlocked developing countries. In February 2025, the Asia-Pacific Forum on Sustainable Development (APFSD) was organized to advance sustainable, science-based, evidence-based, and inclusive solutions for good health, well-being, gender equality, economic growth, and decent work. Concierge Medicine Market Segmentation Analysis: Application Analysis How Primary Care Segment Dominated the Concierge Medicine Market in 2024? The primary care segment dominated the concierge medicine market in 2024 owing to increased accessibility and convenience. Consumers are paying attention to personalized and preventive care, which also improves management of chronic conditions. One of the key drivers of this segment's growth is the rising consumer focus on preventive and proactive health management. Patients are no longer satisfied with reactive, episodic care; instead, they are seeking ongoing monitoring, wellness planning, and chronic disease management, all of which are core offerings in concierge primary care models. This approach is especially valuable for patients with conditions such as diabetes, hypertension, and cardiovascular issues, where continuity of care and close monitoring significantly impact outcomes. The pediatrics segment is expected to grow at the fastest CAGR in the concierge medicine market during the forecast period due to proactive healthcare management. Pediatric care is available in the form of at-home convenience, personalized care, and healthcare attention. Also Read@ Population Health Management Market Set to Reach USD 625.9 B by 2034 – What's Fueling the Surge Ownership Analysis What made Group the Dominant Segment in the Concierge Medicine Market in 2024? The group segment dominated the concierge medicine market in 2024 owing to enhanced patient relationships and reduced administrative burden. Group ownership allows financial stability, predictability, scalability, and resource sharing. The independent segment is expected to grow at the fastest CAGR in the concierge medicine market during the forecast period due to work-life balance and improved patient retention. It causes reduced reliance on insurance reimbursements and streamlined operations. Related Topics You May Find Useful: ➢ Artificial Intelligence (AI) In Precision Medicine Market: The global AI in precision medicine market size was accounted for USD 2.32 billion in 2024 and is anticipated to reach around USD 49.49 billion by 2034, growing at a CAGR of 35.80% from 2025 to 2034. ➢ Regenerative Medicine Market: The global regenerative medicine market size accounted for USD 35.80 billion in 2024 and is predicted to increase from USD 43.80 billion in 2025 to approximately USD 212.80 billion by 2034, expanding at a CAGR of 19.20% from 2025 to 2034. ➢ Complementary and Alternative Medicine Market: The global complementary and alternative medicine market size was valued at USD 154.69 billion in 2024 and is expected to reach over USD 1282.70 billion by 2034, poised to grow at a CAGR of 23.56% from 2025 to 2034. ➢ eHealth 2.0 Market: The global eHealth 2.0 market size accounted for USD 347.54 billion in 2024 and is predicted to increase from USD 381.36 billion in 2025 to approximately USD 879.55 billion by 2034, expanding at a CAGR of 9.73% from 2025 to 2034. ➢ Personalized Medicine Market: The global personalized medicine market was calculated at USD 614.22 billion in 2024 and is predicted to increase from USD 654.46 billion in 2025 to approximately USD 1,315.43 billion by 2034, expanding at a CAGR of 8.10% from 2025 to 2034. Concierge Medicine Market Leading Companies MDVIP SignatureMD Concierge Choice Physicians Crossover Health Specialdocs Consultants Castle Connolly Private Health Partners, LLC Peninsula Doctor Concierge Medicine HealthAssure Private Limited One Medical Priority Physicians of Carmel, Inc. UC San Diego Health What is Going Around the Globe? In September 2024, WhiteGlove announced the launch of AI-Enabled Medical Concierge to assist immigrants in caring for family living abroad. (Source: In October 2024, Sollis Health announced the launch of its first family membership that can recognize the needs of parents for an integrated emergency and everyday care company. (Source: Concierge Medicine Market Segments Covered in the Report By Application Primary Care Cardiology Pediatrics Psychiatry Internal Care Others By Ownership Independent Group By Region North America U.S. Canada Mexico Asia Pacific China Singapore Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor Get Recent News: For the Latest Update Follow Us: LinkedIn | Facebook | TwitterSign in to access your portfolio

AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation

Yahoo

time3 hours ago

  • Yahoo

AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation

Highly selective targeting in Tg AD mouse model improved short-term memory and reduced plaque burden SEATTLE, July 28, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). "We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic," said Valerie Daggett, Ph.D., CEO and Founder of AltPep. "Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers." Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, "Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD." Poster Presentation Details: Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formationPoster #: 104011Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDTLocation: Exhibit Hall DE The poster will also be available in the "Scientific Publications" section of the AltPep website under "Presentations" at Select preclinical data show SOBIN-AD: binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, "These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic." About AltPep CorporationAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. About SOBIN Therapeutics and SOBA DiagnosticsSOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. For more information, please visit and follow us on LinkedIn. View source version on Contacts Media Contact: Susan SharpeLinnden Communicationssusan@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store